TEVA Teva- Pharmaceutical Industries Dashboard

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.

Company profile

Ticker

TEVA

Exchange

NYSE

Website

www.tevapharm.com

CEO

Kaare Schultz

Incorporated

Israel

Location

Israel

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Merck & Co • Allergan • Johnson & Johnson • Abbott Laboratories • Viatris • Bristol-Myers Squibb • Lilly(Eli) & Co • Warner Chilcott • Abbvie ...

Former names

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

SEC CIK

0000818686

Corporate docs

Articles of Incorporation & Bylaws

TEVA stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

10 Health Care Stocks Showing Unusual Options Activity In Today's Session

16 Apr 21

This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. Unusual trading activity could push option prices to exaggerated or underestimated levels.

UK Trial On Mix-Match COVID-19 Vaccines Expanded To Add Moderna, Novavax Shots

14 Apr 21

South African Variant Able To Elude Pfizer/BioNTech' Vaccine Protection, Israeli Study Shows: Report

12 Apr 21

Government, Officials Defend AstraZeneca's COVID-19 Shot: CNBC

8 Apr 21

Teva Canada Announces New Autoinjector for AJOVY for the Preventive Treatment of Migraine in Adults

8 Apr 21

Press releases

Pro users get this 30m faster

Teva to Host Conference Call to Discuss First Quarter 2021 Financial Results at 8 a.m. ET on April 28, 2021

6 Apr 21

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its financial results for the first quarter on Wednesday, April 28, 2021 at 7:00 a.m. ET. Following the

Teva Announces Launch of First Generic Version of AZOPT® (brinzolamide ophthalmic suspension) 1%, used to treat high pressure inside the eye, in the United States

8 Mar 21

Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd.(NYSE and TASE: TEVA), today announced its launch of the first available generic version of AZOPT® (brinzolamide ophthalmic

Teva to Present at the J.P. Morgan 2021 Global High Yield and Leveraged Finance Conference

1 Mar 21

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Executive Vice President & CFO Eli Kalif will present at the J.P. Morgan 2021 Global High Yield and Leveraged Finance Conference on

New Study Published in Cephalalgia Identifies Mechanistic Differences Among CGRP Migraine Treatments

26 Feb 21

Teva Reports Fourth Quarter and Full Year 2020 Financial Results

10 Feb 21

Calendar

10 Feb 21

18 Apr 21

31 Dec 21

Financial summary

Financial statements Chart TEVA financial data

Quarter (USD)	Dec 20	Sep 20	Jun 20	Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	2.18B	2.18B	2.18B	2.18B	2.18B	2.18B
Cash burn (monthly)	(positive/no burn)	(positive/no burn)	(positive/no burn)	297.67M	(positive/no burn)	(positive/no burn)
Cash used (since last report)	n/a	n/a	n/a	1.07B	n/a	n/a
Cash remaining	n/a	n/a	n/a	1.1B	n/a	n/a
Runway (months of cash)	n/a	n/a	n/a	3.7	n/a	n/a

Beta Read what these cash burn values mean

Recent insider trades

TEVA insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
16 Mar 21	Mark Sabag	Ordinary Shares	Sell	Dispose S	No	No	11.2195	127,244	1.43M	20,598
5 Mar 21	Eliyahu Sharon Kalif	Restricted Share Units Ordinary Shares	Grant	Aquire A	No	No	0	85,551	0	85,551
5 Mar 21	Sven Dethlefs	Restricted Share Units Ordinary Shares	Grant	Aquire A	No	No	0	99,809	0	99,809
5 Mar 21	Richard Daniell	Restricted Share Units Ordinary Shares	Grant	Aquire A	No	No	0	90,304	0	90,304
5 Mar 21	Eric Drape	Restricted Share Units Ordinary Shares	Grant	Aquire A	No	No	0	90,304	0	90,304
4 Mar 21	Sven Dethlefs	Ordinary Shares	Sell	Dispose S	No	Yes	10.5661	6,012	63.52K	77,975.7
4 Mar 21	Sven Dethlefs	Ordinary Shares	Option exercise	Aquire M	No	No	0	13,930	0	83,987.7
4 Mar 21	Sven Dethlefs	Restricted Share Units Ordinary Shares	Option exercise	Dispose M	No	No	0	13,930	0	27,861
4 Mar 21	Richard Daniell	Ordinary Shares	Sell	Dispose S	No	Yes	10.5844	7,513	79.52K	20,280
4 Mar 21	Richard Daniell	Ordinary Shares	Option exercise	Aquire M	No	No	0	15,920	0	27,793

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

TEVA institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

11.9% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	2	0	NEW
Opened positions	2	0	NEW
Closed positions	0	0
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	1.26B	0	NEW
Total shares	130.45M	0	NEW
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Capital Research Global Investors	130.14M	$1.26B	NEW
Wellington Management	310.79K	$3M	NEW

Largest transactions	Shares	Bought/sold	Change
Capital Research Global Investors	130.14M	+130.14M	NEW
Wellington Management	310.79K	+310.79K	NEW

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Akorn • Teligent • Spectrum Pharmaceuticals • Actavis • Nektar Therapeutics • Neurocrine Biosciences • Acorda Therapeutics • Innoviva • NeuBase Therapeutics • Amphastar Pharmaceuticals

Management Discussion

The discussion that follows includes a comparison of our results of operations and liquidity and capital resources for fiscal years 2020 and 2019. For a comparison of our results of operations and financial condition for fiscal years 2019 and 2018, see “Item 7—Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our 2019 Annual Report on Form10-K,

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	8th grade Avg

New words: adalimumab, adapt, adapting, African, ago, agreemen, albeit, Alvotech, amplified, Anfinitor, Apixaban, AptensioXR, argument, arm, Ascorbate, Ascorbic, Asian, aspire, Atripla, BCBSM, bellwether, Biden, Brazilian, busin, Bystolic, Cal, capture, Carbamazepine, CAUTIONARY, CECL, celebrate, cerebral, Chloride, chose, circumscribed, Clotrimazole, communicable, conscientiously, conviction, curb, dance, debarment, deceleration, dermatological, detriment, diagnosed, Dimethyl, disciplined, distancing, distinguish, dominant, DSCSA, durability, duringthese, economy, EEA, Efavirenz, Eliquisr, email, emotional, emtricitabine, ensuing, ESG, ess, Etodolac, exclusionary, fear, feel, feeling, female, fifty, Francisco, Goa, guiding, healthy, hesitancy, Humira, hygiene, IFR, Ill, Imiquimod, immunogenicity, imperative, impleme, indicted, indictment, inMarch, inside, irbesartan, issubject, jurisdiction, krona, LAI, learning, lifetime, Lisbon, losartan, mapping, MDI, men, mentoring, MFN, midst, morale, MoviPrep, Nadolol, nebivolol, NOC, nted, numerical, ofproperty, Ointment, online, outbreak, outreach, Pa, palsy, pandemic, PhRMA, play, pleading, pled, PM, postponed, PPE, precautionary, preemption, pride, protectionist, prove, proximity, PSUsgranted, purity, quota, ranitidine, recession, reconsider, redundancy, reinstated, relaunch, reluctance, remotely, repose, resonating, risperidone, Romidepsin, safeguarding, schizophrenia, sending, shape, show, showed, skinny, slower, society, statistical, steeper, strained, Subtopic, survey, survive, Swedish, swelled, tamper, Te, Temozolomide, temporarily, thecourt, Theexpense, theirperformance, thesale, thoughtful, tirelessly, toBB, Tobramycin, toresidual, town, traceability, Truvada, turnover, underscore, uninterrupted, unprecedented, upholding, Upjohn, upper, uptake, upto, va, Virgin, virtual, virtually, Warfarin, wave, week, wellbeing, workplace, Zyclara

Removed: abolishment, actuated, addressed, ADHD, Advair, Aggrenox, Amazon, AmerisourceBergen, announcement, annum, anticompetitive, AOP, appointed, asqui, assured, attempting, Baker, Barr, Barry, BBB, begun, bench, benralizumab, benzoyl, Berkshire, beta, BI, blocking, Boehringer, breath, CAD, cancer, capitalize, capped, Chase, chemotherapy, CHF, children, ciclesonide, cluster, Concerta, conclusion, confirmed, conform, consisting, constant, creditable, declare, declared, declined, deconsolidated, deconsolidation, deem, deliberately, denying, departure, derivatively, devaluation, diligence, dilutive, divert, docket, DuoResp, eleven, Elliot, ELS, episodic, EUR, expanded, exposing, Flovent, Frazer, GBP, gradual, grantor, Grodko, guanfacine, Hathaway, hinder, hip, hydrofluoroalkane, identification, impair, ineffectively, influenced, Ingelheim, insured, Integrating, intensified, interfere, intervene, Intuniv, invalidating, invoiced, irrespective, ixazomib, join, JPMorgan, JPY, Kabi, knee, LABA, language, leasing, levalbuterol, lobby, losing, low, lung, Lupin, matured, McKesson, mesalamine, Modernization, mono, month, Ninlaro, Nordic, opted, ordered, originate, OZ, perception, permanent, permission, permitted, peroxide, Perrigo, persuade, persuasive, pharmacovigilance, PLN, preclude, presiding, prevented, prioritize, punitive, quantification, question, realizing, refundable, rejected, relator, reliably, relocation, remained, repeal, replace, resale, responding, restoring, retroactive, retrospectively, revealed, reverse, saleable, Shire, situated, Slayback, smooth, speaker, stabilizing, substantive, suffered, tam, TD, topical, translate, traumatic, TriCor, underpinning, undo, Unfair, unforeseen, unsealed, USP, utilization, variability, Venezuela, Venezuelan, vi, voluntarily, warehousing, warranty, whistleblower, Wisconsin, withheld, worsen

From filing 10-K 2020 FY